Organization
Institut de Cancerologie de l'Ouest
5 abstracts
1 poster
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Georges Francois Leclerc,
Abstract
Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.Org: Nantes Université, CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, University Hospitals Leuven, Leuven Cancer Institute, and BGOG,
Abstract
Survival outcome prediction of breast carcinomas on whole-slide histopathology images using deep learning.Org: DiaDeep, IHP Group, Loire-Atlantique/Vendée Cancer Registry, Institut de Cancerologie de l'Ouest,
Abstract
ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.Org: Institut Curie, Saint Cloud, France, Paris and Saint Cloud, France, Centre Oscar Lambret, Lille University Hospital,
Abstract
Artificial intelligence to predict homologous recombination deficiency in ovarian cancer from whole-slide histopathological images.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Pathology Department, IHP Group,